drugset
drugset / Trial / NCT02683226

Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS

NCT02683226 ↗

Phase 4 Completed 30 enrolled University Medical Centre Ljubljana
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to determine whether dual treatment with metformin and alogliptin is more effective than treatment with metformin, alogliptin and pioglitazone in the treatment of obese women with polycystic ovary syndrome (PCOS) regarding insulin resistance and beta cell function.

Timeline

Start
2015-03
Primary completion
2015-06
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 30 mg —
Background Alogliptin Unknown 12.5 mg —
Background Metformin Small molecule 1000 mg —

Indications

polycystic ovary syndrome